Revolution Medicines, Inc. (Nasdaq: RVMD), a cancer-focused company in clinical stages, has finalized its acquisition of EQRx, Inc. The merger is anticipated to bring around $1.1 billion in net cash to Revolution Medicines, post wind-down, and transition expenses. Each EQRx common stock share now converts to 0.1112 Revolution Medicines shares. This results in approximately 55 million new common stock shares issued (excluding warrants and earn-out shares). EQRx stocks have halted trading, and their programs are being phased out. CEO Mark A. Goldsmith highlights the transaction’s importance, affirming substantial investments in clinical programs targeting RAS-addicted cancers. The addition of Dr. Sandra Horning, an experienced oncologist, to Revolution Medicines’ board is also noted. The focus remains on advancing their robust pipeline to address patient needs.
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced it has closed its acquisition of EQRx, Inc.
Through the acquisition, Revolution Medicines expects to add approximately $1.1 billion in net cash proceeds to its balance sheet, after estimated post-closing EQRx wind-down and transition costs. Each share of common stock of EQRx issued has been converted into the right to receive 0.1112 shares of common stock of Revolution Medicines. Revolution Medicines expects to issue approximately 55 million shares of its common stock in connection with the merger (excluding assumed warrants and earn-out shares). EQRx common stock has ceased trading on the Nasdaq Global Market and all EQRx programs are being wound down.
“Revolution Medicines has reached an important milestone with the completion of this transaction that brings a significant additional quantum of capital to support our rapidly advancing clinical programs. On the foundation of exciting recent scientific disclosures, we will be able to make significant investments on behalf of the parallel clinical development strategy for our compelling RASMULTI(ON) Inhibitor, RMC-6236, and mutant-selective RAS(ON) Inhibitors, RMC-6291 (G12C), and RMC-9805 (G12D), which we believe have the potential to change the standard of care for patients with RAS-addicted cancers,” said Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines. “We are also delighted to welcome Dr. Sandra Horning, a seasoned oncologist, and late-stage clinical development leader, to the Revolution Medicines board of directors. We remain deeply committed to advancing our rich pipeline of promising oncology assets to address unmet patient needs, and I am extremely grateful to the employees and shareholders of Revolution Medicines and EQRx who have supported us to a successful transaction.”
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Source: Biospace